<div id="readability-page-1">02:13 PM EST, 11/20/2025 (MT Newswires) -- Revelation Biosciences ( REVB ) said Thursday it is on track to hold a meeting with the US Food and Drug Administration later this year following the submission and acceptance of its end-of-phase 1 meeting package to the regulator.The meeting will establish agency feedback and input into the clinical development and regulatory approval pathway for Gemini as a treatment for acute kidney injury, the company said. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

REVB

2025 年 11 月 20 日東部標準時間下午 2:13（MT Newswires）-- Revelation Biosciences（REVB）週四表示，計劃在今年晚些時候與美國食品藥品監督管理局（FDA）舉行會議，此次會議是在向監管機構提交併接受其一期結束會議材料後進行的。該會議將確定機構對 Gemini 作為急性腎損傷治療方案的臨牀開發和監管批准路徑的反饋和意見，公司表示。MT Newswires 不提供投資建議。未經授權的複製是嚴格禁止的

Revelation 表示計劃在今年晚些時候與 FDA 會面